Nonetheless, cyclin-dependent kinase 4 and 6 enzyme inhibitors (CDK4/6 inhibitors) are a relatively new class of medications that were approved in first-line treatment alongside endocrine therapy for HR+/HER-2 negative stage IV breast cancer patients after proving their clinical superiority compared to endocrine monotherapy [5]. This evidence concerns the gene ERBB2 and breast cancer.